Adjuvant Tamoxifen for Male Breast Cancer
Author Information
Author(s): G. Ribeiro, R. Swindell
Primary Institution: The Christie Hospital
Hypothesis
Can adjuvant Tamoxifen improve survival rates in male breast cancer patients?
Conclusion
Adjuvant Tamoxifen significantly improves disease-free survival in male breast cancer patients with minimal side effects.
Supporting Evidence
- Survival rate at 5 years for Tamoxifen treated patients was 61% compared to 44% for historical controls.
- Disease-free survival at 5 years was 56% for treated patients versus 28% for controls.
- Only two patients stopped Tamoxifen due to side effects, indicating good tolerability.
Takeaway
This study shows that giving a medicine called Tamoxifen to men with breast cancer can help them live longer and feel better.
Methodology
Patients with Stage II and operable Stage III male breast cancer were treated with Tamoxifen for 1 to 2 years, and their survival rates were compared to historical controls.
Potential Biases
Potential bias from comparing with historical controls rather than a randomized group.
Limitations
The study lacks a randomized control group due to the rarity of the disease.
Participant Demographics
Patients aged 39 to 78 years, with a mean age of 62; 19 had Stage II disease and 20 had Stage III disease.
Statistical Information
P-Value
0.006
Confidence Interval
42-80%
Statistical Significance
p=0.006
Want to read the original?
Access the complete publication on the publisher's website